Table 5.

Comparison of clinical response between ANA titer increased and no-change patients

	ANA after IFX
EULAR	Increased	No change	P value a
response	(n = 13)	(n = 76)
Good	8%	54%	0.001
(Remission)	(0)	(42%)	0.001
Moderate	15%	20%	0.001
No	77%	26%	0.001

ANAs, antinuclear antibodies; IFX, infliximab.

^aAnalyzed with χ² test.